top of page

Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

  • Dec 22, 2023
  • 1 min read

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance and how the company leverages understandings from this to tackle human disease. On Thursday, Fauna signed a deal with Eli Lilly worth up to $494 million to collaborate on obesity targets.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page